MGNX Quote, Financials, Valuation and Earnings

908 Devices has a net margin of -86.98% compared to Macrogenics's net margin of -103.33%. Macrogenics's return on equity of -60.58% beat 908 Devices's return on equity of -49.84%.

Macrogenics has a consensus price target of $6.00, signalling upside risk potential of 319.58%. On the other hand 908 Devices has an analysts' consensus of $5.50 which suggests that it could fall by -2.14%. Given that Macrogenics has higher upside potential than 908 Devices, analysts believe Macrogenics is more attractive than 908 Devices.

Macrogenics has a beta of 2.201, which suggesting that the stock is 120.129% more volatile than S&P 500. In comparison 908 Devices has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Macrogenics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. 908 Devices offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Macrogenics pays -- of its earnings as a dividend. 908 Devices pays out -- of its earnings as a dividend.

Macrogenics quarterly revenues are $17.7M, which are smaller than 908 Devices quarterly revenues of $18.8M. Macrogenics's net income of -$15.4M is higher than 908 Devices's net income of -$19.4M. Notably, Macrogenics's price-to-earnings ratio is -- while 908 Devices's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Macrogenics is 0.60x versus 3.21x for 908 Devices. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -86.98% compared to Macrogenics's net margin of -49.65%. Macrogenics's return on equity of -60.58% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Macrogenics has a consensus price target of $6.00, signalling upside risk potential of 319.58%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 50.71%. Given that Macrogenics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Macrogenics is more attractive than NovaBay Pharmaceuticals.

Macrogenics has a beta of 2.201, which suggesting that the stock is 120.129% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

Macrogenics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Macrogenics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Macrogenics quarterly revenues are $17.7M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Macrogenics's net income of -$15.4M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Macrogenics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Macrogenics is 0.60x versus 0.15x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of -86.98% compared to Macrogenics's net margin of 16.85%. Macrogenics's return on equity of -60.58% beat Insulet's return on equity of 43.11%.

Macrogenics has a consensus price target of $6.00, signalling upside risk potential of 319.58%. On the other hand Insulet has an analysts' consensus of $319.32 which suggests that it could grow by 2.79%. Given that Macrogenics has higher upside potential than Insulet, analysts believe Macrogenics is more attractive than Insulet.

Macrogenics has a beta of 2.201, which suggesting that the stock is 120.129% more volatile than S&P 500. In comparison Insulet has a beta of 1.263, suggesting its more volatile than the S&P 500 by 26.336%.

Macrogenics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Macrogenics pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

Macrogenics quarterly revenues are $17.7M, which are smaller than Insulet quarterly revenues of $597.5M. Macrogenics's net income of -$15.4M is lower than Insulet's net income of $100.7M. Notably, Macrogenics's price-to-earnings ratio is -- while Insulet's PE ratio is 53.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Macrogenics is 0.60x versus 11.08x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

Skye Bioscience has a net margin of -86.98% compared to Macrogenics's net margin of --. Macrogenics's return on equity of -60.58% beat Skye Bioscience's return on equity of --.

Macrogenics has a consensus price target of $6.00, signalling upside risk potential of 319.58%. On the other hand Skye Bioscience has an analysts' consensus of $15.64 which suggests that it could grow by 795.82%. Given that Skye Bioscience has higher upside potential than Macrogenics, analysts believe Skye Bioscience is more attractive than Macrogenics.

Macrogenics has a beta of 2.201, which suggesting that the stock is 120.129% more volatile than S&P 500. In comparison Skye Bioscience has a beta of 1.741, suggesting its more volatile than the S&P 500 by 74.112%.

Macrogenics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Skye Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Macrogenics pays -- of its earnings as a dividend. Skye Bioscience pays out -- of its earnings as a dividend.

Macrogenics quarterly revenues are $17.7M, which are larger than Skye Bioscience quarterly revenues of --. Macrogenics's net income of -$15.4M is lower than Skye Bioscience's net income of -$9.7M. Notably, Macrogenics's price-to-earnings ratio is -- while Skye Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Macrogenics is 0.60x versus 226.84x for Skye Bioscience. Usually stocks with elevated PS ratios are considered overvalued.